Mustang Bio, Inc.
MBIO
$1.54
-$0.11-6.67%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -56.23% | -55.36% | -57.31% | -33.98% | -34.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -91.88% | -80.89% | -75.25% | -65.03% | -53.81% |
| Operating Income | 91.88% | 80.89% | 75.25% | 65.03% | 53.81% |
| Income Before Tax | 89.78% | 73.28% | 69.47% | 62.61% | 55.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 89.78% | 73.28% | 69.47% | 62.61% | 55.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 89.78% | 73.28% | 69.47% | 62.61% | 55.19% |
| EBIT | 91.88% | 80.89% | 75.25% | 65.03% | 53.81% |
| EBITDA | 92.02% | 81.29% | 75.68% | 65.20% | 53.63% |
| EPS Basic | 97.90% | 90.72% | 85.04% | 77.33% | 67.03% |
| Normalized Basic EPS | 98.64% | 94.02% | 87.69% | 78.90% | 66.15% |
| EPS Diluted | 97.90% | 90.72% | 85.04% | 77.33% | 67.03% |
| Normalized Diluted EPS | 98.64% | 94.02% | 87.69% | 78.90% | 66.15% |
| Average Basic Shares Outstanding | 746.55% | 587.50% | 249.40% | 146.54% | 59.37% |
| Average Diluted Shares Outstanding | 746.55% | 587.50% | 249.40% | 146.54% | 59.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |